Role of the IL-13 system in dopaminergic cell death
IL-13系统在多巴胺能细胞死亡中的作用
基本信息
- 批准号:8846153
- 负责人:
- 金额:$ 41.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-01 至 2016-05-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAgonistAnti-Inflammatory AgentsAnti-inflammatoryBrainCell DeathCell LineCellsCessation of lifeChronicCytokine SignalingDiseaseDopaminergic CellDoseFunctional disorderGenesHealthHumanIL-13Ralpha1Immune systemIn VitroInflammationInjection of therapeutic agentInterleukin-13Interleukin-4InterleukinsKnockout MiceLigandsLipopolysaccharidesMediatingMediator of activation proteinMicrogliaModelingMolecularMusNerve DegenerationNeurodegenerative DisordersNeuronsOxidative StressParkinson DiseasePathogenesisPeripheralPlayPredispositionReactive Oxygen SpeciesReporterRoleSignal PathwaySignal TransductionSignaling MoleculeSourceStressSubstantia nigra structureSystemTestingToxic effectTransgenic MiceTyrosine 3-MonooxygenaseX Chromosomebasecytokinedopaminergic neuronhuman IL13RA1 proteinin vivointerleukin-13 receptormaleneuroinflammationneuron lossneurotoxicnew therapeutic targetnovelpars compactareceptorresearch study
项目摘要
DESCRIPTION (provided by applicant): We hypothesize that the anti-inflammatory cytokines IL-13 and IL-4 play an important role in the death of dopaminergic neurons in the Substantia nigra pars compacta (SNc), the same cells that are lost in human Parkinson's disease (PD). This hypothesis is based on our preliminary studies in mice which showed that interleukin 13 receptor alpha 1 chain (IL-13Ralpha1), is highly expressed in DA neurons in the SNc and that mice that are deficient is this receptor are protected from the loss of dopaminergic (DA) neurons that occurs during chronic peripheral injection with low doses of LPS. Furthermore, in vitro studies using a dopaminergic cell line showed that while IL-13 alone does not have harmful effects on DA neurons, it strongly potentiates the toxicity of mild oxidative stress. Similar resuls were obtained with IL-4, another cytokine capable of activating IL- 13Ralpha1-dependent signaling. Together these results suggest a novel mechanism whereby anti-inflammatory cytokines can contribute to neuronal loss under conditions of stress. We propose to investigate our hypothesis in three specific aims. In SA1, we will determine how the interaction between IL-13 (and IL-4) signaling and oxidative stress induces neuronal damage in vitro. In SA2, we will investigate the contribution of each of these cytokines to neuronal loss in vivo in a model of neuro-inflammation. In SA3, we will determine the cellular source of IL-13 and IL-4 during inflammation. These studies are highly relevant to understanding the role of inflammation in the pathogenesis of PD and may identify novel therapeutic targets for the treatment of this disease.
描述(由申请人提供):我们假设抗炎细胞因子IL-13和IL-4在黑质丘脑部(SNc)多巴胺能神经元死亡中起重要作用,这些细胞在人类帕金森病(PD)中丢失。该假设基于我们在小鼠中的初步研究,该研究显示白细胞介素13受体α 1链(IL-13 Ra 1)在SNc中的DA神经元中高度表达,并且该受体缺陷的小鼠被保护免于在用低剂量LPS进行慢性外周注射期间发生的多巴胺能(DA)神经元的损失。此外,使用多巴胺能细胞系的体外研究表明,虽然单独的IL-13对DA神经元没有有害作用,但它强烈增强了轻度氧化应激的毒性。用IL-4获得了类似的结果,IL-4是另一种能够激活IL-13 Ra 1依赖性信号传导的细胞因子。总之,这些结果表明,一种新的机制,抗炎细胞因子可以有助于神经元损失的条件下的压力。我们建议在三个具体目标中研究我们的假设。在SA 1中,我们将确定IL-13(和IL-4)信号和氧化应激之间的相互作用如何在体外诱导神经元损伤。在SA 2中,我们将在神经炎症模型中研究这些细胞因子中的每一种对体内神经元损失的贡献。在SA 3中,我们将确定炎症期间IL-13和IL-4的细胞来源。这些研究与了解炎症在PD发病机制中的作用高度相关,并可能为治疗这种疾病确定新的治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRUNO CONTI其他文献
BRUNO CONTI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRUNO CONTI', 18)}}的其他基金
Calorie Restriction, Body Temperature and Alzheimers Disease
热量限制、体温和阿尔茨海默病
- 批准号:
10727319 - 财政年份:2023
- 资助金额:
$ 41.77万 - 项目类别:
Do allergens contribute to neurodegeneration?
过敏原会导致神经退行性变吗?
- 批准号:
10542643 - 财政年份:2022
- 资助金额:
$ 41.77万 - 项目类别:
Do allergens contribute to neurodegeneration?
过敏原会导致神经退行性变吗?
- 批准号:
10190052 - 财政年份:2021
- 资助金额:
$ 41.77万 - 项目类别:
Role of the IL-13 system in dopaminergic cell death
IL-13系统在多巴胺能细胞死亡中的作用
- 批准号:
8612661 - 财政年份:2013
- 资助金额:
$ 41.77万 - 项目类别:
Role of the IL-13 system in dopaminergic cell death
IL-13系统在多巴胺能细胞死亡中的作用
- 批准号:
9066821 - 财政年份:2013
- 资助金额:
$ 41.77万 - 项目类别:
Role of the IL-13 system in dopaminergic cell death
IL-13系统在多巴胺能细胞死亡中的作用
- 批准号:
9313963 - 财政年份:2013
- 资助金额:
$ 41.77万 - 项目类别:
Role of the IL-13 system in dopaminergic cell death
IL-13系统在多巴胺能细胞死亡中的作用
- 批准号:
8724574 - 财政年份:2013
- 资助金额:
$ 41.77万 - 项目类别:
Brain interleukin-18 control of food intake and energy expenditure
脑白细胞介素 18 控制食物摄入和能量消耗
- 批准号:
8373865 - 财政年份:2012
- 资助金额:
$ 41.77万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 41.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 41.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 41.77万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 41.77万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 41.77万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 41.77万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 41.77万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 41.77万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 41.77万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 41.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)